Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.

To date, treatment with (or switch to) biosimilar IFX in paediatric patients with IBD have been successful, without affecting efficacy, immunogenicity or safety. However, further studies are warranted, including clinical trials and pharmacovigilance studies.